Pere Fusté

No ORCID on file · 3 papers in corpus · active 2021-2023

Study types

  • article 1
  • other 1

Condition tags

  • endometriosis 2
  • endometrioma 1
  • adenomyosis 1
other 2023
Mapping sentinel lymph nodes in early-stage ovarian cancer (MELISA) trial - a further step towards lymphadenectomy replacement
Gynecologic oncology ·doi:10.1016/j.ygyno.2023.11.007

OBJECTIVE: Sistematic pelvic and para-aortic lymphadenectomy is part of the staging surgery for early-stage epithelial ovarian cancer, with no therapeutic value. The Mapping Sentinel Lymph Nodes In Early-Stage Ovarian Cancer (MELISA) trial …

2022
Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors.
Diagnostics (Basel, Switzerland) ·doi:10.3390/diagnostics12010226

(1) OBJECTIVE: To assess the performance of CA125, HE4, ROMA index and CPH-I index to preoperatively identify epithelial ovarian cancer (EOC) or metastatic cancer in the ovary (MCO). (2) METHODS: single center retrospective study, including…

article 2021
HE4 might be a more useful tumor biomarker to detect malignancy in patients with ovarian endometrioma when malignancy is suspected
The Journal of international medical research ·doi:10.1177/03000605211047701

OBJECTIVE: To analyze the utility of carbohydrate antigen (CA)125 and human epididymis protein 4 (HE4) to detect malignancy in women with ovarian endometriosis, when ovarian cancer is suspected and ultrasonography results are inconclusive. …